Articles tagged with: bb2121
Press Releases»

Summit, NJ and Cambridge, MA (Press Release) – Celgene Corporation (Nasdaq: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced the completion of enrollment for the KarMMa pivotal study of bb2121, the companies’ lead investigational anti-BCMA CAR T cell therapy candidate for patients with relapsed and refractory multiple myeloma. bb2121 is being developed as part of a Co-Development, Co-Promote and Profit Share Agreement between Celgene and bluebird bio.
“We continue to be excited about bb2121 as a potential first-in-class BCMA-targeted therapy for patients with multiple myeloma,” said Alise Reicin, M.D., President, Global …
News»

Updated results of a Phase 1 trial testing bb2121 in relapsed multiple myeloma patients were presented last Friday at the American Society of Clinical Oncology (ASCO) annual meeting. bb2121 is a potential new myeloma treatment in the chimeric antigen receptor (CAR) T-cell class of therapies.
The results presented at this year's ASCO meeting confirm previous findings indicating bb2121 has substantial anti-myeloma activity.
At some of the higher doses of bb2121 tested during the trial, for example, nearly every patient treated with the drug responded to it; the overall response rate was almost …
Deutsch»

Die diesjährige Jahrestagung der American Society of Clinical Oncology (ASCO) begann am Freitag, den 1. Juni, und läuft bis zum Dienstag, den 5.Juni.
Jeden Tag gab es Vorträge über das multiple Myelom. Die Hauptveranstaltung mit Vorträgen über das Myelom fand jedoch am Freitag statt. Forschung, die in Vorträgen zusammengefasst wird, ist in der Regel besonders wichtig, entweder weil das Thema selbst wichtig ist oder weil die Ergebnisse auf umfangreichen Beweisen beruhen (z.B. einer umfangreichen klinischen Studie).
Angesichts der potenziellen Bedeutung der am vergangenen Freitag vorgestellten Forschungsergebnisse befragte Myeloma Beacon drei Myelomexperten zu …
News»

This year’s American Society of Clinical Oncology (ASCO) annual meeting began last Friday and will run through tomorrow.
Multiple myeloma-related presentations have been taking place every day of the meeting. The main myeloma-related oral presentation session of the meeting, however, took place on Friday. Research summarized during oral presentation sessions usually is particularly important, either because the subject itself is important, or because the results are based on substantial amounts of evidence (for example, a sizable clinical trial).
Given the potential importance of the research results presented last Friday, The Beacon asked …
Press Releases»
- bluebird and Celgene will share 50% of U.S. costs and profits
- bluebird to receive milestones and royalties on ex-U.S. sales
Cambridge, MA and Summit, NJ (Press Release) – bluebird bio, Inc. (Nasdaq: BLUE) and Celgene Corporation (Nasdaq: CELG) today announced that the companies have entered into an agreement to co-develop and co-promote bb2121, an investigational anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cell therapy for the potential treatment of patients with relapsed/refractory multiple myeloma in the United States.
“Entering into this co-development and co-promotion partnership with Celgene is a significant step forward in building a fully integrated oncology franchise for bluebird and together, …
Press Releases»
Designations based on preliminary clinical data from ongoing phase I study of bb2121 in heavily pre-treated multiple myeloma
Summit, NJ and Cambridge, MA (Press Release) – Celgene Corporation (NASDAQ:CELG) and bluebird bio, Inc. (NASDAQ:BLUE) today announced that bb2121, a chimeric antigen receptor T-cell (CAR-T) therapy targeting b-cell maturation antigen (BCMA) in previously treated patients with multiple myeloma, has been granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) and PRIority MEdicines (PRIME) eligibility by the European Medicines Agency (EMA).
BTD designation and PRIME eligibility for bb2121 were based on preliminary clinical data from the ongoing phase 1 study CRB-401. Updated data from CRB-401 is scheduled to be …
Press Releases»
- Celgene has agreed to exercise its option to exclusively license bb2121 under global strategic collaboration
- bluebird bio to receive $10 million option exercise payment from Celgene
Cambridge, MA (Press Release) – bluebird bio, Inc. (Nasdaq:BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, announced treatment of the first patient in a Phase 1 study of its product candidate bb2121 in patients with relapsed / refractory multiple myeloma. bb2121 is a chimeric antigen receptor T cell (CAR T) therapy targeting B cell maturation antigen (BCMA), and bluebird bio is developing bb2121 in collaboration with Celgene Corporation. bluebird bio also …